Company Overview and News
2018-09-12 seekingalpha - 5
Discussion: Five Prime Therapeutics' (FPRX) FPA144 (bemarituzumab) plus chemotherapy completed Part 1 of a Phase 1/3 clinical trial evaluating treatment-naive patients with advanced gastric cancer (GC) or cancer of the gastroesophageal junction (GEJ). The trial now moves to its subsequent parts in Phase 3. Overall survival (OS) is the primary endpoint of the trial. Progression-free survival (PFS) and objective response rate (ORR) are the secondary endpoints.
CYCC MASI CYCCP ECYT JNJ ZLAB PRGO FPRX TCON
2018-09-07 sec.gov - 8
2018-09-07 sec.gov - 1
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-209313 PROSPECTUS SUPPLEMENT (to the Prospectus Dated April 4, 2016)
2018-08-29 globenewswire - 1
SAN DIEGO, Aug. 29, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that Charles Theuer, M.D., Ph.D., President and CEO, will present a corporate update at the 2018 Wells Fargo Healthcare Conference at 9:05 pm EDT on Wednesday, September 5, 2018, at the Westin Waterfront in Boston, MA.
2018-08-09 seekingalpha - 1
Good day, ladies and gentlemen, and welcome to the TRACON Pharmaceuticals Second Quarter 2018 Earnings Conference Call. At this time, all callers are in a listen-only mode. After the speakers’ prepared remarks, we will conduct a question-and-answer session and instructions will be given at that time.
tcon-10q_20180630.htm UNITED STATES
2018-07-10 sec.gov - 5
2018-06-15 sec.gov - 8
2018-06-15 seekingalpha - 4
Wright Medical Group N.V. (WMGI) stock prices climbed +4.46% to $25.78 on the news of its receipt of FDA premarket approval (‘PMA) for Augment. Augment, an injectable bone graft, is a combination product containing human platelet derived growth factor (rhPDGF-BB) and a blend of Type I collagen and Beta tricalcium phosphate. The combination is used as a safe and effective alternative to autograft for use in hindfoot and ankle fusion in an easy to use flowable formulation.
SGEN REGN CUTR K RVVTF SCPH PULM AGN MRK CRBP CAH CLSD TCON RVV
2018-06-13 sec.gov - 2
2018-05-31 globenewswire - 1
SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration, announced today that Charles Theuer, M.D., Ph.D., President and CEO, will present at the Jefferies 2018 Healthcare Conference at 12:30 pm EDT on Friday, June 8, 2018, in New York, NY.
SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a biopharmaceutical company that develops targeted therapies for cancer and wet age-related macular degeneration, announced today that it has issued an inducement award to a new executive employee.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to TCON / TRACON Pharmaceuticals, Inc. on message board site Silicon Investor.
as of ET